Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead To Acquire Arresto Biosciences | Contract Pharma

What are you searching for?

Sign in
Breaking News

Gilead To Acquire Arresto Biosciences

Gilead Sciences has signed an agreement to acquire Arresto Biosciences for $225 million and potential payments based on certain sales levels.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences has signed an agreement to acquire Arresto Biosciences for $225 million and potential payments based on certain sales levels. The deal is expected to close in 1Q11, subject to certain closing conditions.

Arresto is development-stage biopharma company focused on medicines to treat fibrotic diseases and cancer. Its lead product, AB0024, is a humanized monoclonal antibody (mAb) targeting the human lysyl oxidase-like-2 (LOXL2) protein currently in a Phase I study in patients with idiopathic pulmonary fibrosis (IPF). A Phase I study of AB0024 in patients with advanced solid tumors is also ongoing.

“Arresto’s R&D expertise is well aligned with Gilead’s areas of focus, including our ongoing clinical program for ambrisentan in IPF,” said Norbert W. Bischofberger, Ph.D., Gilead’s executive vice president, R&D and chief scientific officer. “We look forward to working with the team from Arresto to advance the development of novel therapies for serious fibrotic diseases and explore their potential for the treatment of tumors.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters